Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A LONG TERM, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFECT OF ALBIGLUTIDE, WHEN ADDED TO STANDARD BLOOD GLUCOSE LOWERING THERAPIES, ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Intervention/treatment:
GSK716155 (ALBIGLUTIDE)
Medical condition:
TYPE 2 DIABETES
Protocol code:
GLP116174
Control number:
181262
Status:
Closed
Approved:
February 11, 2015
Date Completed:
Trial phase:
Phase 4
For more information:
ClinicalTrials.gov - NCT02465515
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
GSK Response Center
Organization
GlaxoSmithKline
Phone:
866-435-7343
Sponsor
GLAXOSMITHKLINE INC

Locations

British Columbia

GSK Investigational Site
Kelowna, British Columbia, V1Y 1V6
GSK Investigational Site
Surrey, British Columbia, V3V 0C6
GSK Investigational Site
Victoria, British Columbia, V8R 4R2
GSK Investigational Site
Victoria, British Columbia, V8V 4A

Manitoba

GSK Investigational Site
Winnipeg, Manitoba, 3P

New Brunswick

GSK Investigational Site
Moncton, New Brunswick, E1G 1A7

Newfoundland and Labrador

GSK Investigational Site
St. John's, Newfoundland and Labrador, A1B 3V6

Nova Scotia

GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7
GSK Investigational Site
Truro, Nova Scotia, B2N 1L2

Ontario

GSK Investigational Site
Brampton, Ontario, L6Z 4N5
GSK Investigational Site
Burlington, Ontario, L7M 4Y
GSK Investigational Site
Cambridge, Ontario, N1R 7R1
GSK Investigational Site
Cornwall, Ontario, K6H4M4
GSK Investigational Site
Corunna, Ontario, N0N 1G
GSK Investigational Site
Greater Sudbury, Ontario, P3A 5H
GSK Investigational Site
Hamilton, Ontario, L8L 2X2
GSK Investigational Site
London, Ontario, N5W 6A
GSK Investigational Site
London, Ontario, N6A 4V2
GSK Investigational Site
Sarnia, Ontario, N7T 4X
GSK Investigational Site
Smiths Falls, Ontario, K7A 4W8
GSK Investigational Site
Toronto, Ontario, M9V 4B

Quebec

GSK Investigational Site
Brossard, Quebec, J4Z 2K
GSK Investigational Site
Chicoutimi, Quebec, G7H 7K9
GSK Investigational Site
Greenfield Park, Quebec, J4V 2G
GSK Investigational Site
Greenfield Park, Quebec, J4V 2H1
GSK Investigational Site
Laval, Quebec, H7T 2P5
GSK Investigational Site
Lévis, Quebec, G6V 4Z5
GSK Investigational Site
Montreal, Quebec, H4N 2W
GSK Investigational Site
Saint-Charles-Borromée, Quebec, J6E 6J2
GSK Investigational Site
Saint-Lambert, Quebec, J4P 2J
GSK Investigational Site
Sherbrooke, Quebec, J1J 2E3
GSK Investigational Site
Trois-Rivières, Quebec, G8T 7A1

Results

See the results from the trial NCT02465515. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?